India poised to lead $300 billion genomics patent wave, Vallum report says
Synopsis
A Vallum Capital report argues India is better placed than any other country to capture the $300 billion wave of expiring biologics and gene therapy patents — backed by more WHO-certified plants than any nation, a 16% annual genomics market growth rate, and AI compressing drug discovery to under 18 months. The window is real, but execution on schemes like Biopharma Shakti and Genome India will decide whether India leads or watches.
Key Takeaways
A Vallum Capital report released on 29 July 2026 identifies India as uniquely positioned to capture a $300 billion global patent expiry wave in biologics and gene therapies.
India has more WHO-certified pharmaceutical manufacturing plants than any other country.
The Genome India Project is mapping 10,000 genomes across 99 ethnic groups ; the domestic genomics market is growing at over 16% annually .
AI is compressing drug discovery timelines from a decade to under 18 months ; some platforms run over one million biological experiments weekly .
Biopharma M&A hit $106 billion across 201 deals in H1 2026; biotech VC investment reached $38 billion in 2025 , up 28% year-on-year.
India is uniquely positioned to capitalise on a global genomics revolution and a looming $300 billion patent expiry wave that is driving an aggressive surge in biopharma acquisitions, according to a report released on Wednesday, 29 July 2026 by Vallum Capital. The analysis places India at the centre of what could be the most significant reshaping of the global pharmaceutical order in a generation.
India's Structural Advantage
India hosts more WHO-certified pharmaceutical manufacturing plants than any other country in the world. For three decades, the operating model has been consistent: science invented in the West, scaled and delivered by India. The Vallum Capital report argues that this foundation now positions Indian manufacturers for their largest-ever growth window.
Critically, the medicines approaching patent expiry are not conventional small molecules. They include biologics, gene therapies, and precision oncology drugs — far more complex, and far more lucrative, than the generics India built its reputation on.
Building Domestic Capabilities
India is actively constructing the infrastructure to compete in these advanced segments. The report highlights two flagship initiatives: the Biopharma Shakti scheme and the Genome India Project, which is mapping 10,000 genomes across 99 ethnic groups. India's domestic genomics market is reportedly growing at over 16 per cent annually, signalling that demand and supply-side investment are moving in tandem.
AI and the Compression of Drug Discovery
Globally, artificial intelligence is compressing drug discovery timelines from nearly a decade to under 18 months. Clinical genomic data combined with machine learning is now generating commercial revenue at a scale that validates faster development cycles. Some platforms are reportedly running over one million biological experiments weekly using machine learning — a throughput no conventional research organisation could replicate.
Biopharma M&A and Capital Markets Surge
The financial signals are equally striking. Biopharma mergers and acquisitions reached $106 billion across 201 deals in just the first half of 2026, putting the sector on pace for its strongest full year since before the pandemic. Biotech initial public offerings in the same period raised more capital than the entire sector managed across all of 2025 — a year when only 11 companies went public globally. Venture capital deployed into biotech hit $38 billion in 2025, up 28 per cent year-on-year, according to the report.
What Comes Next
The convergence of patent cliffs, AI-accelerated discovery, and surging capital flows creates a narrow but significant window for Indian pharmaceutical and genomics players. Whether India can translate its manufacturing credentials into leadership in next-generation biologics and gene therapies will depend on execution — both in policy implementation and private-sector R&D investment. The trajectory of initiatives like the Genome India Project will be closely watched as benchmarks of that readiness.
Point of View
But the leap from generics to biologics and gene therapies is not linear — it demands a fundamentally different R&D culture, regulatory agility, and clinical-trial infrastructure that India is still building. The Genome India Project and Biopharma Shakti scheme are credible signals, but schemes announced and schemes executed are two different things. The $300 billion patent cliff is a genuine opportunity, but so was the biosimilars wave a decade ago — and India captured only a fraction of it. The question is not whether India is positioned; it is whether the policy and private-sector execution will be fast enough to meet a window that global capital is already racing toward.
NationPress
29 Jul 2026
Frequently Asked Questions
What is the $300 billion patent expiry wave and why does it matter for India?
The $300 billion patent expiry wave refers to a large cohort of high-value biologics, gene therapies, and precision oncology drugs whose patents are set to expire globally, opening the market to biosimilar and generic manufacturers. India, with more WHO-certified pharma plants than any other country and a fast-growing genomics sector, is considered well-placed to capture a significant share of this opportunity, according to the Vallum Capital report.
What is the Genome India Project?
The Genome India Project is a government-backed initiative mapping 10,000 genomes across 99 ethnic groups in India. It is designed to build a national genomic data foundation that can support drug development, precision medicine, and genomics research at scale.
How fast is India's domestic genomics market growing?
India's domestic genomics market is reportedly growing at over 16 per cent annually, according to the Vallum Capital report released on 29 July 2026. This growth reflects rising investment in genomic diagnostics, research infrastructure, and biopharma capabilities.
What is the scale of global biopharma investment in 2026?
Biopharma M&A reached $106 billion across 201 deals in the first half of 2026 alone, putting the sector on pace for its strongest full year since before the pandemic. Biotech IPOs in H1 2026 raised more capital than the entire sector raised across all of 2025, when only 11 companies went public globally.
How is AI changing drug discovery timelines?
Artificial intelligence is compressing drug discovery timelines from close to a decade to under 18 months, according to the report. Some genomics platforms are now running over one million biological experiments weekly using machine learning, enabling target identification at a scale no conventional research organisation could achieve.
